In November, Reg•Watch blogged about an FDA proposal that would allow drug companies to market drugs for unapproved uses by passing out journal articles and other studies. In a letter to FDA Commissioner Andrew von Eschenbach, Rep. Henry Waxman — whose committee had discovered the proposal — complained that, by creating the loophole, drug companies could promote their drugs using studies they fund themselves, free from FDA oversight.